Zejula®(niraparib) – Expanded indication
April 29, 2020 - GlaxoSmithKline announced the FDA approval of Zejula (niraparib), for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.
Top